CASCADE - Concerted Action on SeroConversion to AIDS and Death in Europe) (FP6-LIFESCIHEALTH) (2006-03-01 - 2010-02-28) (»add to infobox)

Kholoud PORTER, Geneviève CHENE, Ricardo CAMACHO, Giovanni REZZA, Claudia BALOTTA, Julia DEL AMO, Osamah HAMOUDA, Oddbjorn BRUBAKK, Giota TOULOUMI, Patrick FRANCIOLI, Valerie Christine DELPECH, Harold JAFFE, Laurence MEYER, Philippe VANHEMS, Obel NIELS, Maria PRINS, Deenan PILLAY, Claus NIELSEN, Irja LUTSAR, Magdalena ROSINSKA, Tatyana SMOLSKAYA, Dorothy BRAY, Ruslan MALYUTA

MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain), UNIVERSITE VICTOR SEGALEN - BORDEAUX II (FR612 - Gironde) (France), INSTITUTO DE HIGIENE E MEDICINA TROPICAL - UNIVERSIDADE NOVA DE LISBOA (PT171 - Grande Lisboa) (Portugal), ISTITUTO SUPERIORE DI SANITA (ITE43 - Roma) (Italy), UNIVERSITA DEGLI STUDI DI MILANO (ITC45 - Milano) (Italy), UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE - UMH (ES521 - Alicante / Alacant) (Spain), ROBERT KOCH-INSTITUT (DE300 - Berlin) (Germany), ULLEVAL UNIVERSITETSSYKEHUS HF (NO011 - Oslo) (Norway), NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR300 - Attiki) (Greece), HOSPICES CANTONAUX CHUV (CH022 - Freiburg) (Switzerland), HEALTH PROTECTION AGENCY (UKI11 - Inner London - West) (Great Britain), THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), SYDDANSK UNIVERSITET (DK008 - Fyns amt) (Denmark), MUNICIPAL HEALTH SERVICE (NL326 - Groot-Amsterdam) (Netherlands), UNIVERSITY COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), STATENS SERUM INSTITUT (DK001 - København og Frederiksberg kommuner) (Denmark), TARTU UELIKOOL (EE008 - Lõuna-Eesti) (Estonia), PANWTOWY ZAKLAD HIGIENY INSTYTUT NA UKOWO-BADAWCZY (PL127 - Miasto Warszawa) (Poland), SAINT-PETERSBURG PASTEUR INSTITUTE (NoRegion - NoRegion) (Russia), IMMUNOCLIN LIMITED (UKI11 - Inner London - West) (Great Britain), PERINATAL PREVENTION OF AIDS INITIATIVE (NoRegion - NoRegion) (Ukraine)

CASCADE was established in 1997 as a collaboration between the investigators of 22 cohorts of persons with well- estimated dates of HIV seroconversion (seroconverters). It is currently a network of epidemiologists, statisticians, virologists and clinicians from lead HIV institutions in 13 European countries, Australia and Canada. Seroconverters are enrolled into the individual cohorts locally and nationally and are typically followed up life-long. CASCADE's main aim is to monitor newly infected individuals, as well as those already enrolled in studies, over the entire duration of HIV infection. The main premise is that through pooling data we are able to address issues which cannot be reliably addressed from single studies alone. Our main objectives are to: estimate survival expectations and assess changes over time; assess the impact of adverse drug reactions on survival, particularly if therapy is started close to seroconversion, and monitor changes in the cause of death over time; examine any changes in the characteristics of the virus over time; determine the impact of transmitted resistance, virus subtype, and host genetic factors on response to therapy and clinical outcome; characterise the foci of recent HIV epidemics in Eastern Europe; characterise initial disease progression in new epidemic areas; examine the effect of co-infection on HIV disease and response to therapy; and develop new techniques to facilitate the co-ordination of HIV clinical research across European cohorts. Follow-up data from seroconverters are unique in providing information from an individual's initial contact with HIV as events can, therefore, be related to roughly the same fixed time point in their disease. Seroconverters thus provide a unique opportunity to study HIV throughout its whole infection period and also enable us to examine the characteristics of recently acquired HIV infection in the population and changes over time.

PERSONS (23/23)

RELATED NAVIGATION AREA(S) (2/2)